Research Topics
Species | B T HennessySummaryAffiliation: The University of Texas Country: USA Publications
| Collaborators
|
Detail Information
Publications
Non-Hodgkin lymphoma: an updateBryan T Hennessy
Department of Medical Oncology, St James Hospital, Dublin, Ireland
Lancet Oncol 5:341-53. 2004..Here, we review advances in the treatment of NHL that have occurred over the past 10 years...- Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapyBryan T Hennessy
Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 106:1000-6. 2006..The purpose of the current study was to determine long-term outcome in patients achieving a pCR of cytologically proven inflammatory breast carcinoma ALN metastases after primary chemotherapy... - Ovarian cancer: homeobox genes, autocrine/paracrine growth, and kinase signalingB T Hennessy
Department of Molecular Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Int J Biochem Cell Biol 38:1450-6. 2006..As the disease progresses, activation of kinase pathways and continued abnormal autocrine/paracrine stimulation contribute to genomic instability but also identify potential targets for novel therapeutic intervention... 
RPPAML/RIMS: a metadata format and an information management system for reverse phase protein arraysRomesh Stanislaus
Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
BMC Bioinformatics 9:555. 2008..Up to 100 different proteins may be assessed using immunoperoxidase or immunoflorescence techniques in order to determine relative amounts of protein expression in the samples of interest...- Pharmacodynamic markers of perifosine efficacyBryan T Hennessy
Department of Systems Biology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Clin Cancer Res 13:7421-31. 2007..Recent studies suggest that perifosine inhibits the phosphatidylinositol-3'-kinase (PI3K) pathway by preventing cell membrane recruitment of the AKT pleckstrin homology domain... - Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapyBryan T Hennessy
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 23:9304-11. 2005..The purpose of this study was to determine long-term outcome in patients achieving pCR of cytologically proven axillary lymph node (ALN) metastases... 
A systems approach to analysis of molecular complexity in breast cancerBryan T Hennessy
Department of Systems Biology and the Kleberg Center for Molecular Markers, M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 15:417-9. 2009..They identify distinct copy number anomaly patterns in different breast cancer subtypes that implicate a number of genes as potential therapeutic targets and as potential markers of therapy responsiveness...- Biphasic metaplastic sarcomatoid carcinoma of the breastB T Hennessy
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
Ann Oncol 17:605-13. 2006..D. Anderson Cancer Center (MDACC) with 213 MSC and 98 carcinosarcoma patients identified through the Surveillance, Epidemiology and End-Results (SEER) database to describe clinical and pathologic characteristics... - Squamous cell carcinoma of the breastBryan T Hennessy
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
J Clin Oncol 23:7827-35. 2005..D. Anderson Cancer Center (Houston, TX) and a series of 137 patients identified through the Surveillance, Epidemiology, and End Results (SEER) database to make therapy recommendations... - Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literatureB T Hennessy
Department of Breast Medical Oncology and Division of Pharmacy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Ann Oncol 16:1289-96. 2005..We also reviewed the safety profile of capecitabine at these doses and performed a safety review of capecitabine in phase II and III metastatic breast and colorectal cancer trials... - Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristicsBryan T Hennessy
Department of Gynecologic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Cancer Res 69:4116-24. 2009..PIK3CA mutations, EMT, and stem cell-like characteristics likely contribute to the poor outcomes of MBC and suggest novel therapeutic targets... - Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancerRoshan Agarwal
The University of Texas M D Anderson Cancer Center MDACC, Houston, Texas, USA
Clin Cancer Res 15:3654-62. 2009..We studied the expression levels of cyclins B1, D1, and E1 and the implications of cyclin overexpression for patient outcomes in distinct breast cancer subtypes defined by clinical variables and transcriptional profiling... - Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancerChad J Creighton
Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
Breast Cancer Res 12:R40. 2010..We thus examined whether deregulated PI3K signaling in luminal ER+ breast tumors is associated with ER level and activity and intrinsic molecular subtype... - Quantitative proteomic analysis in breast cancerA Tabchy
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Drugs Today (Barc) 47:169-82. 2011..Several initial successes in breast cancer are showing that such information is clinically relevant... - Rak functions as a tumor suppressor by regulating PTEN protein stability and functionEun Kyoung Yim
Department of Systems Biology, The University of Texas M D Anderson Cancer Center, Houston, TX 77054, USA
Cancer Cell 15:304-14. 2009..Furthermore, Rak knockdown was sufficient to transform normal mammary epithelial cells. Therefore, Rak acts as a bona fide tumor suppressor gene through the mechanism of regulating PTEN protein stability and function... - Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancerAna M Gonzalez-Angulo
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 15:2472-8. 2009..To examine the androgen receptor (AR) levels in breast cancer and to assess the impact of AR expression on patient outcomes... - Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapyMark S Carey
Department of Systems Biology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Clin Cancer Res 16:2852-60. 2010..Using reverse phase protein array, we measured protein expression associated with response to primary chemotherapy in patients with advanced-stage, high-grade serous ovarian cancer... - Trends for inflammatory breast cancer: is survival improving?Ana M Gonzalez-Angulo
Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030 4009, USA
Oncologist 12:904-12. 2007..Clinical trials focusing on the management of this aggressive disease are warranted. Disclosure of potential conflicts of interest is found at the end of this article... - Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancerAna M Gonzalez-Angulo
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Clin Cancer Res 17:1082-9. 2011..Survival was estimated by Kaplan-Meier method and compared with log-rank. Cox proportional hazards models were fit to determine the independent association of mutation status with outcome... - Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancerSiqing Fu
Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 117:1661-9. 2011..A phase 1b-2a clinical trial of this sequential combination of azacitidine and carboplatin was initiated in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer... - Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosisMandi M Murph
Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
PLoS ONE 4:e5583. 2009..However, there is an absence of systematic data critically analyzing the transcriptional changes induced by LPA in ovarian cancer... - An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancerKatherine Stemke-Hale
Department of Systems Biology, The University of Texas MD Anderson Cancer, Houston, Texas 77030, USA
Cancer Res 68:6084-91. 2008..The specific aberration present may have implications for the selection of PI3K-targeted therapies in hormone receptor-positive breast cancer... - Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trialsEmer O Hanrahan
Department of Breast Medical Oncology, Unit 1354, UT MD Anderson Cancer Center, PO Box 301439, Houston, Texas 77230-1439, USA
Expert Opin Pharmacother 6:1477-91. 2005.... - Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line setEun Sung Park
Department of Melanoma Medical Oncology and Department of Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0904, Houston, TX 77030, USA
Mol Cancer Ther 9:257-67. 2010.... - Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristicsBryan T Hennessy
University of Texas MD Anderson Cancer Center, Houston, TX 77230-1439, USA
Nat Clin Pract Oncol 2:598-9. 2005 - Adjuvant therapy for breast cancerB T Hennessy
Department of Breast Medical Oncology, UT MD Anderson Cancer Center, Houston, TX 77030, USA
Minerva Ginecol 57:305-26. 2005..Results from several large randomized studies are expected shortly and will define the use of trastuzumab in this clinical setting... - Exploiting the PI3K/AKT pathway for cancer drug discoveryBryan T Hennessy
Department of Molecular Therapeutics, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Nat Rev Drug Discov 4:988-1004. 2005..This warrants exploiting the PI3K/AKT pathway for cancer drug discovery... - Ovarian cancerBryan T Hennessy
Department of Gynecologic Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Lancet 374:1371-82. 2009.... - Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approachMatthias Niedermeier
Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
Blood 113:5549-57. 2009.... - Ovarian cancer: linking genomics to new target discovery and molecular markers--the way aheadBryan T Hennessy
Department of Molecular Therapeutics, MD Anderson Cancer Center, Houston, TX, USA
Adv Exp Med Biol 617:23-40. 2008 - Breast carcinoma with neuroendocrine differentiation and myocardial metastasesBryan T Hennessy
Department of Gynecologic Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
Clin Breast Cancer 7:892-4. 2007..Better understanding of the cellular origin and molecular pathogenesis of this relatively enigmatic rare disease is required... - New approaches in the treatment of myelofibrosisBryan T Hennessy
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 103:32-43. 2005..g., thalidomide), tyrosine kinase inhibitors (e.g., imatinib mesylate), farnesyl transferase inhibitors (e.g., R115777), and other agents are reviewed, in addition to the potential roles of autologous and allogeneic SCT... - DNA methylation in haematological malignancies: the role of decitabineBryan T Hennessy
Department of Leukaemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Expert Opin Investig Drugs 12:1985-93. 2003..Phase II and III studies are currently ongoing to evaluate decitabine, both alone and in combination, in various stages of these haematological malignancies... - A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancerKatrien Berns
Division of Molecular Carcinogenesis and Center for Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
Cancer Cell 12:395-402. 2007..Thus, assessment of PI3K pathway activation may provide a biomarker to identify patients unlikely to respond to trastuzumab-based therapy... - Primary angiosarcomas of the breastTaimur Sher
Department of Internal Medicine, Mount Sinai Medical Center, Miami Beach, Florida, USA
Cancer 110:173-8. 2007..The purpose of the study was to describe the clinicopathologic characteristics and clinical outcomes of patients with primary breast angiosarcoma...